204 related articles for article (PubMed ID: 36068486)
1. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
3. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
[TBL] [Abstract][Full Text] [Related]
5. The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China.
Guo H; Yao Y; Zhou J; Wang S; Wang Y; Zheng D
Ren Fail; 2023; 45(2):2253922. PubMed ID: 37724562
[TBL] [Abstract][Full Text] [Related]
6. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
[TBL] [Abstract][Full Text] [Related]
7. Response to immunosuppressive therapy in PLA
Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
[TBL] [Abstract][Full Text] [Related]
8. Phospholipase A2 Receptor Antibodies and Clinical Prognosis in Patients with Idiopathic Membranous Nephropathy: An Updated Systematic Review and Meta-Analysis.
Zhang J; Fan Z; Wang P; Zhang AH
Kidney Blood Press Res; 2023; 48(1):102-113. PubMed ID: 36720217
[TBL] [Abstract][Full Text] [Related]
9. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
[TBL] [Abstract][Full Text] [Related]
11. Association of serum mannose-binding lectin, anti-phospholipase A2 receptor antibody and renal outcomes in idiopathic membranous nephropathy and atypical membranous nephropathy: a single center retrospective cohort study.
Zhao Y; Cai M; Jiang Z; Dong B; Yan Y; Wang Y; Zuo L
Ren Fail; 2022 Dec; 44(1):428-433. PubMed ID: 35272568
[TBL] [Abstract][Full Text] [Related]
12. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
[TBL] [Abstract][Full Text] [Related]
13. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
14. The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy.
Chen Y; Xu Y; Chen S; Yu Y; Zhu X; Chen J
Ren Fail; 2023; 45(2):2264939. PubMed ID: 37814415
[TBL] [Abstract][Full Text] [Related]
15. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
16. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Characteristics and Outcomes of PLA
Luo J; Yuan Y; Tian J; Zhou Z; Su C; Yang F; Wang G
Am J Kidney Dis; 2022 Sep; 80(3):364-372. PubMed ID: 35288217
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases.
Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA
J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies.
Li X; Shen Y; Li Y; Ma L; Sun Q
Ren Fail; 2024 Dec; 46(1):2297015. PubMed ID: 38275176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
